Eupraxia Pharmaceuticals Stock Quote EPRX - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

3.70

Bid

3.44

Ask

3.70

Volume

4,865

3.54 Day's Range 3.60

3.25 52 Week Range 8.46

Market Cap

100.943M

Previous Close

3.50

Open

3.54

Last Trade

100

3.7

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

16,572

Shares Outstanding

27,282,000

Dividend Yield

PE Ratio

-3.48

Earnings Per Share (EPS)

-1.03

Revenue

Net Profit

-28.22M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.eupraxiapharma.com

Headquarters

Victoria, British Columbia, Can

Founded

1970

Eupraxia Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the Toronto Stock Exchange with ticker EPRX. The last closing price for Eupraxia Pharmaceuticals was $3.50. Over the last year, Eupraxia Pharmaceuticals shares have traded in a share price range of $ 3.25 to $ 8.46.

Eupraxia Pharmaceuticals currently has 27,282,000 shares outstanding. The market capitalization of Eupraxia Pharmaceuticals is $95.49 million. Eupraxia Pharmaceuticals has a price to earnings ratio (PE ratio) of -3.48.

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo PR Newswire VICTORIA, BC, July 8, 2024 VICTORIA, BC, July 8, 2024 /PRNewswire/ - Eupraxia...

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024 PR Newswire VICTORIA, BC, July 3...

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders PR Newswire VICTORIA, BC, June 6, 2024 VICTORIA, BC, June 6, 2024 /PRNewswire/ - Eupraxia...

Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024

Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024 PR Newswire VICTORIA, BC, June 5, 2024...

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Canada NewsWire VICTORIA, BC, May 23, 2024 Eight of nine patients...

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024 Canada NewsWire VICTORIA, BC, May 22...

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR Newswire VICTORIA, BC, May 21, 2024 Trial's first...

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024 PR...

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire VICTORIA, BC, May 8, 2024 Eupraxia common shares now listed on the Nasdaq Capital...

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board PR Newswire VICTORIA, BC, May 2, 2024 --Advisory Board to Provide Guidance for Company's Eosinophilic Esophagitis...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.175	4.96453900709	3.525	3.7	3.3	6990	3.51825179	CS
4	0.19	5.41310541311	3.51	3.74	3.25	12174	3.51117227	CS
12	-0.06	-1.59574468085	3.76	4.1	3.25	16572	3.76526626	CS
26	-1.6	-30.1886792453	5.3	7.64	3.25	42446	4.41434586	CS
52	-4	-51.9480519481	7.7	8.46	3.25	32805	5.22685216	CS
156	-0.1	-2.63157894737	3.8	9.1	0.8	26919	4.17057386	CS
260	-4.05	-52.2580645161	7.75	9.1	0.8	25689	4.25738515	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.57M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	260.07k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.06M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.69M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.92M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	716.26k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.02M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	408.45M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.33M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.49M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.71M